Peficitinib: First Global Approval

doi:10.1007/s40265-019-01131-y

2019-05-15

PRE

Anthony Markham *

Susan J. Keam

DOI：10.1007/s40265-019-01131-y

原文链接

原文求助

摘要

En 中文

Peficitinib [Smyraf((R)) (Astellas Pharma)] is a Janus kinase (JAK)1, JAK2, JAK3 and tyrosine kinase (Tyk)2 (pan-JAK) inhibitor recently approved in Japan for the treatment of rheumatoid arthritis. Inhibition of JAK suppresses the activation of cytokine signalling pathways involved in inflammation and joint destruction in rheumatoid arthritis. Peficitinib has been shown to significantly improve ACR20 and other measures of disease severity and to reduce the mean modified total Sharp score change from baseline in clinical trials. This article summarizes the milestones in the development of peficitinib leading to this first approval as a treatment for rheumatoid arthritis in patients who have an inadequate response to conventional therapies.

Keyword:

JANUS KINASE INHIBITOR

SEVERE RHEUMATOID-ARTHRITIS

JAK INHIBITOR

MODERATE

PHARMACOKINETICS

EFFICACY

SAFETY

AI总结

对已上传原文的论文进行重点信息的提取，主要内容包括：简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。

期刊

Drugs

IF:

14.4

论文数:

8.4K

被引数:

2.3W

机构

暂无机构信息

引用论文

Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis

ARTHRITIS & RHEUMATOLOGY

IF10.9

2017-04-26

OAAI

Genovese, Mark C.; Greenwald, Maria; Codding, Christine; Zubrzycka-Sienkiewicz, Anna; Kivitz, Alan J.; Wang, Annie; Shay, Kathyjo; Wang, Xuegong; Garg, Jay P.; Cardiel, Mario H.

Peficitinib, a JAK Inhibitor, in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate

ARTHRITIS & RHEUMATOLOGY

IF10.9

2017-03-29

OAAI

Kivitz, A. J.; Gutierrez-Urena, S. R.; Poiley, J.; Genovese, M. C.; Kristy, R.; Shay, K.; Wang, X.; Garg, J. P.; Zubrzycka-Sienkiewicz, A.

Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study

ANNALS OF THE RHEUMATIC DISEASES

IF20.6

2016-06-01

134

OAAI

Takeuchi, Tsutomu; Tanaka, Yoshiya; Iwasaki, Manabu; Ishikura, Hiroaki; Saeki, Satoshi; Kaneko, Yuichiro

A novel JAK inhibitor, peficitinib, demonstrates potent efficacy in a rat adjuvant-induced arthritis model

JOURNAL OF PHARMACOLOGICAL SCIENCES

IF2.9

2017-01-01

OAAI

Ito, Misato; Yamazaki, Shunji; Yamagami, Kaoru; Kuno, Masako; Morita, Yoshiaki; Okuma, Kenji; Nakamura, Koji; Chida, Noboru; Inami, Masamichi; Inoue, Takayuki; Shirakami, Shohei; Higashi, Yasuyuki

Production from dairy cows of semi-industrial quantities of milk-protein concentrate (MPC) containing efficacious anti-Candida albicansIgA antibodies

Journal of Dairy Research

IF0

2007-04-30

PREAI

Alison J Hodgkinson; Richard D Cannon; Ann R Holmes; Frank J Fischer; Dawn J Willix-Payne

Immunohistological localization of IgG1, IgA and secretory component in the bovine mammary gland during involution

Cell and Tissue Research

IF0

1988-01-01

PREAI

S. Zou; W. L. Hurley; H. M. Hegarty; B. L. Larson; D. R. Nelson